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T1 Mapping and the MyocardiumChristopher M. Kramer, MD,* Y. Chandrashekhar, MD,y Jagat Narula, MD, PHDzC ardiac magnetic resonance (CMR) has mademajor inroads in the past 2 decades thanksto its ability to characterize myocardial tis-
sue noninvasively (1). It began with late gadolinium
enhancement as a means to assess myocardial infarct
size (2), for which it is now the gold standard. Over
time, it was recognized that other nonischemic causes
of myocardial ﬁbrosis visible on pathology, such
as hypertrophic cardiomyopathy, sarcoidosis, and
so on, could be visualized with late gadolinium
enhancement (3). More than a decade ago, a new
pulse sequence called modiﬁed Look-Locker inver-
sion recovery was developed for T1 mapping (4) that
enables the quantitative evaluation of myocardial T1
either without contrast, so-called native T1, or post-
contrast. A Society for Cardiovascular Magnetic Reso-
nance consensus document has been published
regarding the optimal approaches to T1 mapping (5).
Native T1 is especially useful in patients who cannot
receive gadolinium-based contrast agents because of
stage 4 or 5 chronic kidney disease. Native T1 is high-
est in patients with amyloidosis, many of whom have
chronic kidney disease (6). It is elevated to an inter-
mediate degree in hypertrophic cardiomyopathy and
other nonischemic cardiomyopathies (7). Post-
contrast T1 mapping is used to calculate extracellular
volume (ECV), which is elevated in the setting
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mation (1). Elevated ECV has been documented in
hypertensive heart disease (8), hypertrophic cardio-
myopathy (9), and heart failure with preserved ejec-
tion fraction (10). Increased ECV has been associated
with adverse short-term cardiac prognosis in a
diverse patient population (11).
T1 mapping is an extremely versatile technique.
This issue of iJACC is dedicated to a variety of appli-
cations and potential uses of T1 mapping in cardio-
vascular disease. The promise is remarkable and
increasingly tangible. For example, the group at Ox-
ford has studied native T1 at rest and with adenosine
stress, showing that native T1 is sensitive to changes
in myocardial blood volume, which may be a sensi-
tive marker of ischemia (12). They found that normal
myocardium increased native T1 with adenosine by
more than 6%, whereas infarcted myocardium
showed essentially no increase. Ischemic myocar-
dium showed an intermediate increase of approxi-
mately 4%. This was a pilot study with only 10
patients with coronary artery disease included, and
thus larger studies are clearly needed to further
examine this hypothesis. A major advance here is the
ability to perform stress CMR studies without using
gadolinium. Because the T1 changes with stress are
small, reproducibility and reliability must be estab-
lished so as to know whether such studies could be
useful in individual patients. Sensitivity to blood
volume changes offers exciting possibilities in other
myocardial diseases.
The paper by Treibel et al. (13) represents a
potential major advance in the ease of measuring
ECV using post-contrast T1 mapping. Typically,
ECV requires measurement of the hematocrit (Hct)
for accurate assessment, which can be problematic
in outpatients coming for routine CMR, who
may not have other reasons for a blood draw. This
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89multicenter group of investigators demonstrates a
method for estimating Hct using the T1 of the
blood pool. Substituting the estimated Hct into the
formula for calculating ECV enables the measure-
ment of a “synthetic” ECV that correlates closely
with the standard ECV measure (r2 ¼ 0.97). The
investigators demonstrate excellent performance in
a validation cohort of 213 patients. Using synthetic
ECV would preclude the need to draw Hct in pa-
tients who otherwise do not need to have blood
drawn.
Two pieces in this issue examine the utility of T1
mapping in congenital heart disease. The Boston
Children’s group measured ECV in both the left and
right ventricles in 84 patients with repaired tetral-
ogy of Fallot (14). They found increased left ven-
tricular (LV) ECV in 11 of the patients and right
ventricular (RV) ECV in 9 patients. LV and RV ECV
correlated reasonably well with each other. Inter-
estingly, increased RV ECV was associated more with
volume rather than pressure overload. The in-
vestigators explain this by noting that cell volume as
well as ECV increases with pressure overload. In
addition, with myocardial atrophy in volume over-
load, ECV, which is a relative value, increases.
Increased LV ECV was associated with arrhythmias.
This is the ﬁrst study to systematically compare LV
and RV ECV and thus adds important information to
the understanding of the potential use of T1 map-
ping in RV diseases. The research correspondence by
Broberg et al. (15) also examines T1 mapping in 52
adults with repaired tetralogy of Fallot compared
with 22 controls, but their analysis was limited to
the left ventricle. This group found that 15 of the
patients had ECVs $30, and 1 in 3 of these had atrial
arrhythmias or cardiovascular death, compared with
6% of the remaining 30 patients. Although the
numbers are small, the study adds weight to the
concept that elevated ECV is associated with adverse
prognosis.
The prognostic power of T1 mapping was studied
by Kammerlander et al. (16) in 473 patients referred
for CMR, but excluding patients with amyloidosis,
hypertrophic cardiomyopathy, and Anderson-Fabry
disease. They demonstrate a good correlation with
ECV by tissue FAXS analysis and ECV on CMR,
further validating the measure. They also found
that higher ECV by tertile was associated with
cardiovascular hospitalization and cardiac death
among imaging values, although when adjusted
for clinical parameters, it was no longer statis-
tically signiﬁcant. However, ECV has been shown tohave independent prognostic power in larger pa-
tient groups (11).
Puntmann et al. (17) performed another prognos-
tic study, but speciﬁcally in nonischemic dilated
cardiomyopathy. They studied 637 patients and
followed them for 22 months and observed 28 deaths,
of which 22 were cardiac. Because Hct was not
measured concurrently, ECV could not be measured
in every patient. Interestingly, native T1 was an in-
dependent predictor of mortality, as well as heart
failure mortality and hospitalizations, which consti-
tuted a secondary endpoint. However, we cannot be
sure that ECV isn’t as good as native T1 in this
particular population, because they were not directly
compared. That being said, this study demonstrates
that T1 mapping has prognostic utility in all comers
referred for CMR as well as those particularly
referred for evaluation of nonischemic dilated
cardiomyopathy.
Finally, Taylor et al. (18) review the technical
background and potential clinical applications of T1
mapping in a comprehensive look at the ﬁeld by
innovators in this area (18). Where does the ﬁeld go
from here? The initial validation studies are in the
books, but further research is clearly needed to fully
ﬂesh out the clinical utility of both native T1 and
ECV. We are at the very early stages of under-
standing the prognostic utility of these measures,
and this needs to be compared with the prognostic
utility of LV function and/or late gadolinium
enhancement in the various myocardial diseases in
which it has been studied. In addition, little is
known presently about the change over time in any
of these measures. Understanding the latter is
essential to consider using native T1 or ECV as
endpoints for clinical trials of novel therapeutics
aimed at improving clinical outcomes. In that regard,
studies are now beginning of novel agents to remove
amyloid protein from patients with amyloidosis us-
ing T1 mapping as surrogate endpoints in addition to
clinical endpoints. Such studies will help to validate
the utility of these techniques. In summary, we at
iJACC hope that we have brought to the reader
important insights into a rapidly evolving and novel
area that promises exciting developments and new
applications over the next few years for cardiovas-
cular imagers.
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